Investor Overview

Corporate Profile

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are pursuing additional indications including type 2 diabetes and other chronic conditions.

Corporate Presentation
More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund . Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy to insulin, for the treatment of type 1 diabetes, expected to initiate patient enrollment in the
View HTML
PDF Version
Toggle Summary vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
HIGH POINT, N.C. , March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the
View HTML
PDF Version
Toggle Summary vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
HIGH POINT, N.C. , March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that Company
View HTML
PDF Version
Toggle Summary vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024 HIGH POINT, N.C. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin   (TTP399) as an adjunctive
View HTML
PDF Version
More >>
Webcasts
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)  
Volume
Data as of

Data Provided by Refinitiv. Minimum 15 minutes delayed.